Educational Materials For the Public
…of 50 for educational events. Rack Cards Resources for Newly Diagnosed Melanoma Patients Recursos Para Pacientes Recién Diagnosticados Con Melanoma…
Educational Materials For the Public
…of 50 for educational events. Rack Cards Resources for Newly Diagnosed Melanoma Patients Recursos Para Pacientes Recién Diagnosticados Con Melanoma…
Start a Fundraiser
Start a Fundraiser AIM at Melanoma invites you to raise money for the cure however you want to raise it.…
Subscribe to Our Newsletter
Subscribe to Our Newsletter Stay connected with AIM at Melanoma and get the latest news in breakthrough melanoma research. …
Benefits of Participating in a Clinical Trial
While a clinical trial is a good choice for some people, this treatment option has both possible benefits and…
Indiana
[aim_melanoma_specialist] Find a Specialist Indiana University Cancer Center * Interndisciplinary Melanoma Clinic 535 Barnhill Drive Indianapolis, IN 46202-5289 317-944-0920 cancer.iu.edu…
Maryland
[aim_melanoma_specialist] Find a Specialist The Sidney Kimmel Comprehensive Cancer Center * Johns Hopkins Melanoma Program 401 North Broadway Baltimore, MD…
Utah
[aim_melanoma_specialist] Find a Specialist Huntsman Cancer Institute * University of Utah Melanoma & Cutaneous Oncology Program 2000 Circle of Hope…
Ohio
…http://cancer.uc.edu Rekha Chaudhary, MD Cleveland Clinic Cleveland Clinic Main Campus 9500 Euclid Avenue Cleveland, OH 44195 216-444-7923 http://my.clevelandclinic.org Thach-Giao Truong,…
Rhode Island
[aim_melanoma_specialist] Find a Specialist Rhode Island Hospital Interdisciplinary Melanoma Program 593 Eddy St., APC Building, 10th Floor Providence, Rhode Island…
Levine Cancer Institute | October 24
…Survivorship Care Plans Thomas R. Rapisardo, MD Survivorship Levine Cancer Institute 10:40 AM Resources for the Melanoma Patients Samantha Guild,…
Recent Posts
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026